Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034803401> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2034803401 endingPage "122" @default.
- W2034803401 startingPage "114" @default.
- W2034803401 abstract "Despite progress in surgical and adjuvant therapy, a subset of patients with early stage breast cancer experience disease recurrence and/or distant metastases. Disseminated tumor cells (DTCs) in the bone marrow are believed to be the source of late relapses in bone and other tissues. Bone is the most common site of breast cancer metastasis, and agents that modify the bone microenvironment could therefore affect the disease course. Bisphosphonates are an effective bone-targeted therapeutic option for preventing cancer treatment- induced bone loss (CTIBL) in pre- and postmenopausal women with breast cancer. Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone. Preclinical and clinical data also suggest anticancer synergy between cytotoxic chemotherapy agents and bisphosphonates. Recent trials of zoledronic acid in the adjuvant setting in breast cancer have demonstrated reduced disease recurrence in bone and other sites. Currently, several ongoing clinical trials are evaluating whether antiresorptives can inhibit disease recurrence and the development of bone metastases from breast cancer. Based on recent data, the role of bisphosphonates in the breast cancer setting is expected to expand in the future. With recent changes to treatment guidelines, routine use of bisphosphonates to prevent bone loss during adjuvant therapy is likely to become standard practice, especially for patients receiving endocrine therapy. Furthermore, the use of zoledronic acid to reduce the risk of recurrence is emerging based on ongoing clinical research. Keywords: Adjuvant therapy, Anticancer, Bisphosphonate, Breast cancer, Zoledronic acid, micrometastases, cytotoxic agents, disease-free survival (DFS), clodronate-treated patients" @default.
- W2034803401 created "2016-06-24" @default.
- W2034803401 creator A5025718393 @default.
- W2034803401 date "2012-02-01" @default.
- W2034803401 modified "2023-10-14" @default.
- W2034803401 title "Anticancer Activity of Bisphosphonates in Breast Cancer" @default.
- W2034803401 doi "https://doi.org/10.2174/187152012799014931" @default.
- W2034803401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21864231" @default.
- W2034803401 hasPublicationYear "2012" @default.
- W2034803401 type Work @default.
- W2034803401 sameAs 2034803401 @default.
- W2034803401 citedByCount "6" @default.
- W2034803401 countsByYear W20348034012013 @default.
- W2034803401 countsByYear W20348034012014 @default.
- W2034803401 countsByYear W20348034012015 @default.
- W2034803401 countsByYear W20348034012017 @default.
- W2034803401 countsByYear W20348034012023 @default.
- W2034803401 crossrefType "journal-article" @default.
- W2034803401 hasAuthorship W2034803401A5025718393 @default.
- W2034803401 hasConcept C121608353 @default.
- W2034803401 hasConcept C126322002 @default.
- W2034803401 hasConcept C143998085 @default.
- W2034803401 hasConcept C2776169692 @default.
- W2034803401 hasConcept C2776326535 @default.
- W2034803401 hasConcept C2776541429 @default.
- W2034803401 hasConcept C2777251235 @default.
- W2034803401 hasConcept C2777863537 @default.
- W2034803401 hasConcept C2777982462 @default.
- W2034803401 hasConcept C530470458 @default.
- W2034803401 hasConcept C673006 @default.
- W2034803401 hasConcept C71924100 @default.
- W2034803401 hasConceptScore W2034803401C121608353 @default.
- W2034803401 hasConceptScore W2034803401C126322002 @default.
- W2034803401 hasConceptScore W2034803401C143998085 @default.
- W2034803401 hasConceptScore W2034803401C2776169692 @default.
- W2034803401 hasConceptScore W2034803401C2776326535 @default.
- W2034803401 hasConceptScore W2034803401C2776541429 @default.
- W2034803401 hasConceptScore W2034803401C2777251235 @default.
- W2034803401 hasConceptScore W2034803401C2777863537 @default.
- W2034803401 hasConceptScore W2034803401C2777982462 @default.
- W2034803401 hasConceptScore W2034803401C530470458 @default.
- W2034803401 hasConceptScore W2034803401C673006 @default.
- W2034803401 hasConceptScore W2034803401C71924100 @default.
- W2034803401 hasIssue "2" @default.
- W2034803401 hasLocation W20348034011 @default.
- W2034803401 hasLocation W20348034012 @default.
- W2034803401 hasOpenAccess W2034803401 @default.
- W2034803401 hasPrimaryLocation W20348034011 @default.
- W2034803401 hasRelatedWork W1951451169 @default.
- W2034803401 hasRelatedWork W2054423421 @default.
- W2034803401 hasRelatedWork W2066082630 @default.
- W2034803401 hasRelatedWork W2078392470 @default.
- W2034803401 hasRelatedWork W2116456578 @default.
- W2034803401 hasRelatedWork W2297653040 @default.
- W2034803401 hasRelatedWork W2378640608 @default.
- W2034803401 hasRelatedWork W2541953178 @default.
- W2034803401 hasRelatedWork W2558313572 @default.
- W2034803401 hasRelatedWork W2518317038 @default.
- W2034803401 hasVolume "12" @default.
- W2034803401 isParatext "false" @default.
- W2034803401 isRetracted "false" @default.
- W2034803401 magId "2034803401" @default.
- W2034803401 workType "article" @default.